NYMOX PHARMACEUTICAL CORP (NYMX)       0.42  +0.01 (+1.3%)

0.42  +0.01 (+1.3%)

BSP733981026 - Common Stock - Premarket: 0.4 -0.02 (-4.76%)

NYMOX PHARMACEUTICAL CORP0.42

NASDAQ:NYMX (12/6/2022, 9:52:00 PM)+0.01 (+1.3%)

Premarket: 0.4 -0.02 (-4.76%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-16 2022-11-16/dmh Earnings (Next) N/A N/A
Ins Owners 5.15% Inst Owners 0.72%
Market Cap 38.33M Shares 91.27M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts N/A
IPO 11-26 1997-11-26

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

NYMX Daily chart

Company Profile

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. The company is headquartered in Saint-Laurent, Quebec and currently employs 3 full-time employees. The firm is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (prostate enlargement, BPH) and for low-grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke. The Company’s lead drug candidate for BPH FT has completed Phase III development in more than 70 clinical centers in the United States. FT has completed a phase II trial in the United States. The company has also developed the AlzheimAlert test. The firm operates in Canada, the United States and Switzerland.

Company Info

NYMOX PHARMACEUTICAL CORP

St. Laurent, 9900 Cavendish Blvd Suite 306

Saint-Laurent QUEBEC H4M 2V2

P: 18009369669.0

CEO: Paul Averback

Employees: 3

Website: http://www.nymox.com/

NYMX News

News Image2 days ago - Nymox Pharmaceutical CorporationNYMOX Announces New Marketing Submission for NYMOZARFEX™ for BPH

IRVINE, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that a new...

News Image2 days ago - Nymox Pharmaceutical CorporationNYMOX Announces New Marketing Submission for NYMOZARFEX™ for BPHNews Image12 days ago - Nymox Pharmaceutical CorporationMay 2023 Market Cap Requirement Update

IRVINE, Calif., Nov. 25, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) reports that on November 18, 2022 the...

News Image12 days ago - Nymox Pharmaceutical CorporationMay 2023 Market Cap Requirement UpdateNews Image3 months ago - Nymox Pharmaceutical CorporationNYMOX Provides Current Update

IRVINE, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on business...

News Image5 months ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

We're starting off the day with a breakdown of the biggest pre-market stock movers investors will want to watch on Tuesday!

NYMX Twits

Here you can normally see the latest stock twits on NYMX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example